Pharmacogenomics: implications for laboratory medicine

被引:21
作者
Schmitz, G [1 ]
Aslanidis, C [1 ]
Lackner, KJ [1 ]
机构
[1] Univ Hosp Regensburg, Inst Clin Chem & Lab Med, D-93042 Regensburg, Germany
关键词
pharmacogenomics; laboratory medicine; diagnostics;
D O I
10.1016/S0009-8981(01)00424-7
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Pharmacogenomics deals with the interactions of individual genetic constitution with drug therapy. It has potentially far reaching consequences for drug development and future treatment strategies, but also for clinical in vitro diagnostics. With increasing knowledge about interactions between genes and drug treatment, there will be an equally increasing demand for rapid and reliable diagnostic tests prior to the institution of therapy. In fact. it is very likely that pharmacogenetic tests will make up a significant proportion of total molecular biology testing in the coming years. Therefore, this review focuses on the implications of pharmacogenomics on the clinical laboratory. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:43 / 53
页数:11
相关论文
共 45 条
  • [1] A SINGLE AMINO-ACID OF THE CHOLECYSTOKININ-B GASTRIN RECEPTOR DETERMINES SPECIFICITY FOR NONPEPTIDE ANTAGONISTS
    BEINBORN, M
    LEE, YM
    MCBRIDE, EW
    QUINN, SM
    KOPIN, AS
    [J]. NATURE, 1993, 362 (6418) : 348 - 350
  • [2] Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions
    Bertz, RJ
    Granneman, GR
    [J]. CLINICAL PHARMACOKINETICS, 1997, 32 (03) : 210 - 258
  • [3] Single-nucleotide polymorphism in the human mu opioid receptor gene alters β-endorphin binding and activity:: Possible implications for opiate addiction
    Bond, C
    LaForge, KS
    Tian, MT
    Melia, D
    Zhang, SW
    Borg, L
    Gong, JH
    Schluger, J
    Strong, JA
    Leal, SM
    Tischfield, JA
    Kreek, MJ
    Yu, L
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (16) : 9608 - 9613
  • [4] CLINICAL IMPLICATIONS OF VARIABLE ANTIARRHYTHMIC DRUG-METABOLISM
    BUCHERT, E
    WOOSLEY, RL
    [J]. PHARMACOGENETICS, 1992, 2 (01): : 2 - 11
  • [5] The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry
    Chen, SQ
    Chou, WH
    Blouin, RA
    Mao, ZP
    Humphries, LL
    Meek, C
    Neill, JR
    Martin, WL
    Hays, LR
    Wedlund, PJ
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (05) : 522 - 534
  • [6] Template-directed dye-terminator incorporation (TDI) assay: A homogeneous DNA diagnostic method based on fluorescence resonance energy transfer
    Chen, XN
    Kwok, PY
    [J]. NUCLEIC ACIDS RESEARCH, 1997, 25 (02) : 347 - 353
  • [7] Chen YL, 1998, T NONFERR METAL SOC, V8, P5
  • [8] ELECTROPHORESIS FOR GENOTYPING - MICROTITER ARRAY DIAGONAL GEL-ELECTROPHORESIS ON HORIZONTAL POLYACRYLAMIDE GELS, HYDROLINK, OR AGAROSE
    DAY, INM
    HUMPHRIES, SE
    [J]. ANALYTICAL BIOCHEMISTRY, 1994, 222 (02) : 389 - 395
  • [9] Delahunty C, 1996, AM J HUM GENET, V58, P1239
  • [10] Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment
    Drazen, JM
    Yandava, CN
    Dubé, L
    Szczerback, N
    Hippensteel, R
    Pillari, A
    Israel, E
    Schork, N
    Silverman, ES
    Katz, DA
    Drajesk, J
    [J]. NATURE GENETICS, 1999, 22 (02) : 168 - 170